Nicox SA (0RCQ) Price & Analysis

Compare

4 Followers

0RCQ Stock Chart & Stats

Day’s Range― - ―

52-Week Range€0.17 - €0.65

Previous CloseN/A

Volume120.00

Average Volume (3M)110.56K

Market Cap

€26.79M

Enterprise Value€23.97M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.56

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding72,506,165

10 Day Avg. Volume71,228

30 Day Avg. Volume110,560

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€1.50

Price Target Upside316.67% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial HealthThe agreement with Kowa reduces Nicox's debt by using 70% of the upfront payment, improving the company's financial health.

Financial PerformanceThe licensing agreement provides Nicox with an upfront payment of €7.5M and potential development and sales milestones of up to €191.5M, depending on the Denali trial outcome.

Market OpportunitiesThe Denali trial results could lead to NDA submissions in the U.S. and China, opening up opportunities in a large glaucoma market.

Bears Say

Commercial Success ChallengesFailure to achieve commercial success due to market size, penetration rate, and competition poses a risk.

Regulatory Approval RisksRisks include failure of pipeline candidates in clinical trials, failure to secure regulatory approval, and failure to achieve commercial success due to market size, penetration rate, and competition.

Nicox SA News

Positive Outlook for Nicox SA Driven by Successful NCX 470 Trial and Strategic Partnerships

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA and increased the price target...

9d ago

Buy Rating for Nicox SA Driven by Strategic Developments and Financial Prospects

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with...

24d ago

Nicox SA’s Strategic Developments and Promising Trials Justify Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Nicox SA, retaining the price target of...

1M ago

Nicox SA’s Strategic Advancements and Clinical Progress Bolster Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Nicox SA (0RCQ – Research Report) today and...

3M ago

Nicox SA: Promising Financial Stability and Clinical Advancements Drive Buy Rating

Nicox SA (0RCQ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

6M ago

Nicox Completes U.S. Patient Recruitment for NCX 470 Trial

Nicox SA (FR:ALCOX) has released an update. Nicox SA has announced the completion of patient recruitment in the...

1y ago

Nicox SA to Engage in Major Industry Conferences

Nicox SA (FR:ALCOX) has released an update. Nicox SA, an international ophthalmology company, is set to participate in...

1y ago

Nicox SA Reports Solid Q2 2024 Financials

Nicox SA (FR:ALCOX) has released an update. Nicox SA, a French ophthalmology company, reported a second-quarter 2024 revenue...

1y ago

Nicox SA Announces New Leadership Appointments

Nicox SA (FR:ALCOX) has released an update. Nicox SA has announced the appointment of seasoned biotech executive Damian...

1y ago

Nicox SA Reschedules Shareholder Meeting

Nicox SA (FR:ALCOX) has released an update. Nicox SA, an international ophthalmology company, has announced the postponement of...

1y ago

0RCQ FAQ

What was Nicox SA’s price range in the past 12 months?

Nicox SA lowest share price was €0.17 and its highest was €0.65 in the past 12 months.

What is Nicox SA’s market cap?

Nicox SA’s market cap is €26.79M.

When is Nicox SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nicox SA’s earnings last quarter?

Nicox SA released its earnings results on Oct 16, 2024. The company reported -€0.068 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.068.

Is Nicox SA overvalued?

According to Wall Street analysts Nicox SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nicox SA pay dividends?

Nicox SA does not currently pay dividends.

What is Nicox SA’s EPS estimate?

Nicox SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nicox SA have?

Nicox SA has 72,506,165 shares outstanding.

What happened to Nicox SA’s price movement after its last earnings report?

Nicox SA reported an EPS of -€0.068 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Nicox SA?

Currently, no hedge funds are holding shares in GB:0RCQ

Company Description

Nicox SA

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

Nicox SA (0RCQ) Earnings & Revenues

Historic Earnings Reports

0RCQ Stock 12 Month Forecast

Average Price Target

€1.50

▲(316.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Jul<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.4107692307692308,0.5015384615384615,0.5923076923076923,0.6830769230769231,0.7738461538461539,0.8646153846153846,0.9553846153846155,1.0461538461538462,1.136923076923077,1.2276923076923076,1.3184615384615386,1.4092307692307693,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.4107692307692308,0.5015384615384615,0.5923076923076923,0.6830769230769231,0.7738461538461539,0.8646153846153846,0.9553846153846155,1.0461538461538462,1.136923076923077,1.2276923076923076,1.3184615384615386,1.4092307692307693,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.4107692307692308,0.5015384615384615,0.5923076923076923,0.6830769230769231,0.7738461538461539,0.8646153846153846,0.9553846153846155,1.0461538461538462,1.136923076923077,1.2276923076923076,1.3184615384615386,1.4092307692307693,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.41,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >